Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611735 | 0.87 | CA2 (0.40) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL6545333 | 0.87 | CA2 (0.40) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL2911556 | 0.85 | CA2 (0.39) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL12541972 | 0.85 | APAF1 (0.46) | MMECA2CA4FOLH1 | |
| SCHEMBL2915366 | 0.85 | CA2 (0.43) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL2911554 | 0.85 | CA2 (0.39) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL2915369 | 0.85 | CA2 (0.43) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL27383424 | 0.83 | CA2 (0.42) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL27382800 | 0.83 | CA2 (0.38) | MAPTMMEALDH1A1CA2CA4 | |
| SCHEMBL14199861 | 0.83 | ECE1 (0.47) | MAPTCYP2D6CYP2C19ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490189-A | Amino acid modified silicon ball and preparation method and application thereof | 中国科学院赣江创新研究院 | 2025-02-21 | — | — | CN | claimed |
| CN-119490189-A | Amino acid modified silicon ball and preparation method and application thereof | 中国科学院赣江创新研究院 | 2025-02-21 | — | — | CN | disclosed |
| US-20220340599-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220002317-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002317-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | MAPT 874/4885MME 3233/4885CYP2D6 4515/4885 |
| US-20220340599-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | MAPT 874/4885MME 3233/4885CYP2D6 4515/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | MAPT 4669/4885MME 1100/4885CYP2D6 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.